Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Vir Biotechnology (VIR – Research Report) on November 10 and set a price target of $24.00.
Roanna Ruiz assigned a Buy rating to Vir Biotechnology primarily because of the promising results from the company’s Phase 2 trials for HDV and HBV. Ruiz believes that the directionally positive outcomes from these trials could support the further development of Vir’s combo regimen of VIR-2218 siRNA/VIR-3434 mAb entry inhibitor for both indications. She particularly highlighted the potential of HDV to become a significant area of investor interest due to the solid data from the Phase 2 SOLSTICE study.
Furthermore, Ruiz anticipates that investor focus will remain on whether this combo can meet the regulatory approval standards for HDV, and how its long-term data might compare to alternative treatments like Gilead’s Hepcludex. Moreover, the upcoming 6-month post-treatment HBV data for VIR-2218/VIR-3434 is expected to provide a better understanding of how its efficacy compares to GSK’s bepirovirsen for HBV functional cure. Therefore, based on these factors, Ruiz is confident in her Buy rating for Vir Biotechnology.
In another report released on November 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $95.00 price target.
VIR’s price has also changed dramatically for the past six months – from $24.440 to $8.790, which is a -64.03% drop .
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vir Biotechnology (VIR) Company Description:
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Read More on VIR:
- Vir Biotechnology price target lowered to $27 from $41 at Barclays
- Vir Biotechnology files automatic mixed securities shelf
- Vir Biotechnology reports Q3 EPS ($1.22), consensus ($1.21)
- Vir Biotechnology appoints Jennifer Towne, Ph.D., as Chief Scientific Officer
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
